1. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results
   Shinya Rai et al, 2022, Haematologica CrossRef
2. Advances and Perspectives in the Treatment of T-PLL
   Till Braun et al, 2020, Current Hematologic Malignancy Reports CrossRef
3. Divergent Effects of EZH1 and EZH2 Protein Expression on the Prognosis of Patients with T-Cell Lymphomas
   Franziska Lea Schümann et al, 2021, Biomedicines CrossRef
4. Targeting Protein Degradation Pathways in Tumors: Focusing on their Role in Hematological Malignancies
   Anna Wolska-Washer et al, 2022, Cancers CrossRef
5. Tumor Immune Microenvironment in Lymphoma: Focus on Epigenetics
   Daniel J. García-Domínguez et al, 2022, Cancers CrossRef
6. The Status and Prospects of Epigenetics in the Treatment of Lymphoma
   Jiaxin Liu et al, 2022, Frontiers in Oncology CrossRef
7. Therapies of Hematological Malignancies: An Overview of the Potential Targets and Their Inhibitors
   Suvankar Banerjee et al, 2021, Current Chemical Biology CrossRef
8. Role of Histone Deacetylases in T-Cell Development and Function
   Monika Pieniawska et al, 2022, International Journal of Molecular Sciences CrossRef